100% Same
Salt CompositionEffectivenessStrength
Top Branded
Substitute
Salt Composition in bothVenlafaxine 37.5mg
Our Recommendation
Venlift OD 37.5mg Capsule 10s
904+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
Depression / Anxiety disorder
Customers also bought
More About Venlasys 37.5 Capsule ER
Benefits
In Depression Venlasys 37.5 Capsule ER helps in maintaining the balance of certain chemicals in the brain that affect mood and behavior. This improves your mood, relieves anxiety, tension, helps you sleep better, and increases your energy levels. Venlasys 37.5 Capsule ER prevents extreme mood changes and helps you feel less agitated. You may experience fewer episodes of depression and low mood. In Anxiety disorder Venlasys 37.5 Capsule ER works by stopping your brain from releasing the chemicals that make you feel anxious so it can reduce the symptoms of excessive anxiety and worry. It can also reduce feelings of restlessness, tiredness, difficulty concentrating, irritability, and sleep problems that often come with Anxiety disorder. It will therefore help you go about your daily activities more easily and be more productive. Keep taking this medicine even if you feel well. Stopping suddenly can cause serious problems.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Venlasys 37.5 Capsule ER is to be taken with food.
How it works
Venlasys 37.5 Capsule ER works by increasing the levels of chemical messengers (serotonin and noradrenaline), natural substances in the brain that help maintain mental balance.
Unsafe: Avoid consuming alcohol with Venlasys 37.5 Capsule ER as it is deemed unsafe.
Seek medical advice from your doctor: Venlasys 37.5 Capsule ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Seek medical advice from your doctor: Venlasys 37.5 Capsule ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. Babies should be monitored for excessive sleepiness and adequate weight gain.
Not Safe: Venlasys 37.5 Capsule ER may cause side effects which could affect your ability to drive. As side effects of Venlasys 37.5 Capsule ER are dizziness, confusion and eye sight changes such as blurred vision and this may affect your ability to drive.
Caution Advised: Venlasys 37.5 Capsule ER should be used with caution in patients with kidney disease. Dose adjustment of Venlasys 37.5 Capsule ER may be needed. Doctor consultation is advised.
Caution Advised: Venlasys 37.5 Capsule ER should be used with caution in patients with liver disease. Dose adjustment of Venlasys 37.5 Capsule ER may be needed. Doctor consultation is advised.
What if I forget to take it?
If a dose of Venlasys 37.5 Capsule ER is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
Plot No 315, Industrial Area Phase-2, Panchkula Haryana)-134109
References
Stahl SM, editor. Venlafaxine. In: Stahl's Essential Pschopharmacology: Prescriber's Guide. 5th ed. New York, New York: Cambridge University Press; 2014. pp. 721-26
DeBattista C. Antidepressant Agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 513
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1466
Venlafaxine (19 Mar. 2019)
Drugs and Lactation Database (LactMed) (20 Feb. 2020)
Central Drugs Standard Control Organisation (CDSCO) (19 Mar. 2019)
Venlafaxine hydrochloride (18 Feb. 2025)
Venlafaxine Extended-Release (18 Feb. 2025)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
